*Division of Neurology, University of British Columbia
‡Department of Pathology and Laboratory Medicine, University of British Columbia
§Department of Pathology and Laboratory Medicine, Vancouver General Hospital
∥Department of Pathology and Laboratory Medicine, St. Paul’s Hospital, Providence Health Care, Vancouver, BC, Canada
†Department of Neurosciences, University of California San Diego, La Jolla, CA
Patient consent for publication: Obtained from next-of-kin.
I.R.A.M. reports personal fees from Prevail Therapeutics, outside the submitted work. H.H.F. reports UCSD service agreements for consulting with Eisai, Merck, Tau RX, Samus, Arkuda, Samumed, Axon Neurosciences, Roche/Genentech for DMC and DSMB activities, Tau Consortium for Scientific Advisory Board; grant funding through UCSD from Toyama Pharmaceuticals, AC Immune Biohaven Pharmaceuticals, and Vivoryon (Probiodrug); travel support from Toyama, Axon Neurosciences and Alion Pharmaceuticals and speaker fees to UCSD from World Events Forum, Optum Health, and Medscape, outside the submitted work. The remaining authors declare no conflicts of interest.
Reprints: Mari L. DeMarco, PhD, DABCC, FCACB, Department of Pathology and Laboratory Medicine, St Paul’s Hospital, 1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6 (e-mail: [email protected]).
